Near-genomewide RNAi screening for regulators of BRAFV600E-induced senescence identifies RASEF, a gene epigenetically silenced in melanoma

Pigment Cell and Melanoma Research

Volumn 27, Issue 4, 2014, Pages 640-652

  Kaplon, Joanna ^a   Hömig Hölzel, Cornelia ^a,c   Gao, Linda ^b   Meissl, Katrin ^a,d   Verdegaal, Els M E ^b   van der Burg, Sjoerd H ^b   van Doorn, Remco ^b   Peeper, Daniel S ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

BRAF; Melanoma; Methylation; RASEF; Screen; Senescence

Indexed keywords

B RAF KINASE; GALACTOSIDASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; BRAF PROTEIN, HUMAN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PTEN PROTEIN, HUMAN; RASEF PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER GROWTH; CANCER SCREENING; CUTANEOUS MELANOMA; DNA METHYLATION; EPIGENETICS; GENOME ANALYSIS; HUMAN; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; ONCOGENE; RNA INTERFERENCE; SENESCENCE; AMINO ACID SUBSTITUTION; CELL AGING; CELL CYCLE CHECKPOINT; GENETICS; METABOLISM; MISSENSE MUTATION; PATHOLOGY; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; CELL AGING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; HUMANS; MELANOMA; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS GUANINE NUCLEOTIDE EXCHANGE FACTORS; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS;

EID: 84902535383     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12248     Document Type: Article

References (64)

1. Acosta, J.C., O'Loghlen, A., Banito, A. et al. (2008). Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-1018.
2. Acosta, J.C., Banito, A., Wuestefeld, T. et al. (2013). A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15, 978-990.
3. Aird, K.M., Zhang, G., Li, H., et al. (2013). Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Reports 3, 1252-1265.
4. Baker, D.J., Wijshake, T., Tchkonia, T., LeBrasseur, N.K., Childs, B.G., van de Sluis, B., Kirkland, J.L., and van Deursen, J.M. (2011). Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232-236.
5. Berger, M.F., Levin, J.Z., Vijayendran, K. et al. (2010). Integrative analysis of the melanoma transcriptome. Genome Res. 20, 413-427.
6. Berger, M.F., Hodis, E., Heffernan, T.P. et al. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506.
7. Berns, K., Hijmans, E.M., Mullenders, J. et al. (2004). A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437.
8. Bogdan, I., Smolle, J., Kerl, H., Burg, G., and Böni, R. (2003). Melanoma ex naevo: a study of the associated naevus. Melanoma Res. 13, 213-217.
9. Campisi, J. (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513-522.
10. Collado, M., and Serrano, M. (2010). Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 10, 51-57.
11. Coppé, J.-P., Patil, C.K., Rodier, F., Sun, Y., Muñoz, D.P., Goldstein, J., Nelson, P.S., Desprez, P.-Y., and Campisi, J. (2008). Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853-2868.
12. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
13. Dadzie, O.E., Yang, S., Emley, A., Keady, M., Bhawan, J., and Mahalingam, M. (2009). RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Br. J. Dermatol. 160, 368-375.
14. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E., You, M.J., DePinho, R.A., McMahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
15. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
16. Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, M., Rubelj, I., and Pereira-Smith, O. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367.
17. Gao, L., Smit, M.A., van den Oord, J.J. et al. (2013). Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma. Pigment Cell Melanoma Res. 26, 542-554.
18. Garcia-Manero, G., Daniel, J., Smith, T.L., Kornblau, S.M., Lee, M.-S., Kantarjian, H.M., and Issa, J.-P.J. (2002). DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin. Cancer Res. 8, 2217-2224.
19. Garraway, L.A., Widlund, H.R., Rubin, M.A. et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.
20. Gray-Schopfer, V.C., Cheong, S.C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z.A., Marais, R., Wynford-Thomas, D., and Bennett, D.C. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496-505.
21. Hayflick, L. (1965). The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614-636.
22. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
23. Hömig-Hölzel, C., van Doorn, R., Vogel, C., Germann, M., Cecchini, M.G., Verdegaal, E., and Peeper, D.S. (2011). Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence. EMBO J. 30, 1753-1765.
24. Huff, V. (2011). Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat. Rev. Cancer 11, 111-121.
25. Jiang, P., Du, W., Mancuso, A., Wellen, K.E., and Yang, X. (2013). Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 493, 689-693.
26. Jönsson, G., Bendahl, P.-O., Sandberg, T., Kurbasic, A., Staaf, J., Sunde, L., Crüger, D.G., Ingvar, C., Olsson, H., and Borg, A. (2005). Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32. J. Natl Cancer Inst. 97, 1377-1382.
27. Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., Stockert, E., Day, R.S., Johnson, B.E., and Skolnick, M.H. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440.
28. Kang, T.-W., Yevsa, T., Woller, N. et al. (2011). Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547-551.
29. Kaplon, J., Zheng, L., Meissl, K. et al. (2013). A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 498, 109-112.
30. Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
31. Krizhanovsky, V., Yon, M., Dickins, R.A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., and Lowe, S.W. (2008). Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657-667.
32. Kuilman, T., and Peeper, D.S. (2009). Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 9, 81-94.
33. Kuilman, T., Michaloglou, C., Vredeveld, L.C.W., Douma, S., van Doorn, R., Desmet, C.J., Aarden, L.A., Mooi, W.J., and Peeper, D.S. (2008). Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019-1031.
34. Kuilman, T., Michaloglou, C., Mooi, W.J., and Peeper, D.S. (2010). The essence of senescence. Genes Dev. 24, 2463-2479.
35. Lin, W.M., Baker, A.C., Beroukhim, R. et al. (2008). Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 68, 664-673.
36. Lowe, S.W., Cepero, E., and Evan, G. (2004). Intrinsic tumour suppression. Nature 432, 307-315.
37. Maat, W., Beiboer, S.H.W., Jager, M.J., Luyten, G.P.M., Gruis, N.A., and van der Velden, P.A. (2008). Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 49, 1291-1298.
38. Mathew, R., Karantza-Wadsworth, V., and White, E. (2007). Role of autophagy in cancer. Nat. Rev. Cancer 7, 961-967.
39. Michaloglou, C., Vredeveld, L.C.W., Soengas, M.S., Denoyelle, C., Kuilman, T., van der Horst, C.M.A.M., Majoor, D.M., Shay, J.W., Mooi, W.J., and Peeper, D.S. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
40. Mooi, W.J., and Peeper, D.S. (2006). Oncogene-induced cell senescence-halting on the road to cancer. N. Engl. J. Med. 355, 1037-1046.
41. Nakamura, S., Takemura, T., Tan, L. et al. (2011). Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells. Carcinogenesis 32, 1758-1772.
42. Narita, M., Nũnez, S., Heard, E., Narita, M., Lin, A.W., Hearn, S.A., Spector, D.L., Hannon, G.J., and Lowe, S.W. (2003). Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716.
43. Oshita, H., Nishino, R., Takano, A., et al. (2013). RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer. Mol Cancer Res 11, 937-951.
44. Palavalli, L.H., Prickett, T.D., Wunderlich, J.R. et al. (2009). Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat. Genet. 41, 518-520.
45. Peeper, D.S., Shvarts, A., Brummelkamp, T., Douma, S., Koh, E.Y., Daley, G.Q., and Bernards, R. (2002). A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat. Cell Biol. 4, 148-153.
46. Pollock, P.M., Harper, U.L., Hansen, K.S. et al. (2003). High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19-20.
47. Prickett, T.D., Agrawal, N.S., Wei, X., Yates, K.E., Lin, J.C., Wunderlich, J.R., Cronin, J.C., Cruz, P., Rosenberg, S.A., and Samuels, Y. (2009). Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 41, 1127-1132.
48. Prickett, T.D., Wei, X., Cardenas-Navia, I. et al. (2011). Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat. Genet. 43, 1119-1126.
49. Rodier, F., Coppé, J.-P., Patil, C.K., Hoeijmakers, W.A.M., Muñoz, D.P., Raza, S.R., Freund, A., Campeau, E., Davalos, A.R., and Campisi, J. (2009). Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 11, 973-979.
50. Rothhammer, T., and Bosserhoff, A.-K. (2007). Epigenetic events in malignant melanoma. Pigment Cell Res. 20, 92-111.
51. Rowland, B.D.B., Bernards, R.R., and Peeper, D.S.D. (2005). The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 7, 1074-1082.
52. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602.
53. Sherr, C.J. (2006). Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6, 663-673.
54. Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L., and Robertson, G.P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010.
55. Toyota, M., Kopecky, K.J., Toyota, M.O., Jair, K.W., Willman, C.L., and Issa, J.P. (2001). Methylation profiling in acute myeloid leukemia. Blood 97, 2823-2829.
56. Vandesompele, J., de Preter, P.K., Pattyn, F., Poppe, B., van Roy, R.N., de Paepe, P.A. and Speleman, F. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, research0034.
57. Vredeveld, L.C.W., Rowland, B.D., Douma, S., Bernards, R., and Peeper, D.S. (2010). Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E. Carcinogenesis 31, 201-207.
58. Vredeveld, L.C.W., Possik, P.A., Smit, M.A. et al. (2012). Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 26, 1055-1069.
59. Wajapeyee, N., Serra, R.W., Zhu, X., Mahalingam, M., and Green, M.R. (2008). Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132, 363-374.
60. Wang, X., Yue, P., Chan, C.-B., Ye, K., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Fu, H., Khuri, F.R., and Sun, S.-Y. (2007). Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol. Cell. Biol. 27, 7405-7413.
61. Wei, X., Walia, V., Lin, J.C. et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446.
62. Yazdi, A.S., Palmedo, G., Flaig, M.J. et al. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest Dermatol. 121, 1160-1162.
63. Yokoyama, S., Woods, S.L., Boyle, G.M. et al. (2011). A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480, 99-103.
64. Zhang, R., Chen, W., and Adams, P.D. (2007). Molecular dissection of formation of senescence-associated heterochromatin foci. Mol. Cell. Biol. 27, 2343-2358.